Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis

Yuee Cai; Zhangyan Guan; Yin Tong; Weiyang Zhao; Jiangwen Zhang; Ling Peng; Philip P. C. Ip; Sally K. Y. To; Alice S. T. Wong

doi:10.1093/procel/pwaf019

Protein Cell ›› 2025, Vol. 16 ›› Issue (7) : 602 -608. DOI: 10.1093/procel/pwaf019

LETTER

Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis

Author information +

History +

PDF (14166KB)

Cite this article

Download citation ▾

Yuee Cai, Zhangyan Guan, Yin Tong, Weiyang Zhao, Jiangwen Zhang, Ling Peng, Philip P. C. Ip, Sally K. Y. To, Alice S. T. Wong. Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis. Protein Cell, 2025, 16(7): 602-608 DOI:10.1093/procel/pwaf019

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Aiello NM, Maddipati R, Norgard RJ et al. EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell 2018;45:681–695.e4.

[2]	Banushi B, Joseph SR, Lum B et al. Endocytosis in cancer and cancer therapy. Nat Rev Cancer 2023;23:450–473.

[3]	Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941–951.

[4]	Carvalho S, Reis CA, Pinho SS. Cadherins glycans in cancer: sweet players in a bitter process. Trends Cancer 2016;2:519–531.

[5]	Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell 2023;186:1564–1579.

[6]	Hallas-Potts A, Dawson JC, Herrington CS. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci Rep 2019;9:5515.

[7]	Li Y, Lv Z, Zhang S et al. Genetic fate mapping of transient cell fate reveals N-cadherin activity and function in tumor metastasis. Dev Cell 2020;54:593–607.e5.

[8]	Loret N, Denys H, Tummers P et al. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers 2019;11:838.

[9]	Ma J, To SKY, Fung KSW et al. P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis. Cell Rep 2024;44:115096.

[10]	Meng J. Distinct functions of dynamin isoforms in tumorigenesis and their potential as therapeutic targets in cancer. Oncotarget 2017;8:41701–41716.

[11]	Mrozik KM, Blaschuk OW, Cheong CM et al. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer 2018;18:939.

[12]	Nieto MA, Huang RY, Jackson RA et al. EMT: 2016. Cell 2016;166:21–45.

[13]	Ru B, Tong Y, Zhang J. MR4Cancer: a web server prioritizing master regulators for cancer. Bioinformatics 2019;35:636–642.

[14]	To SKY, Mak ASC, Eva Fung YM et al. β-catenin downregulates Dicer to promote ovarian cancer metastasis. Oncogene 2017;36:5927–5938.

[15]	Xu L, Wang J, Liu B et al. HDAC9 contributes to serous ovarian cancer progression through regulating epithelial-mesenchymal transition. Biomedicines 2022;10:374.